|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2005-2-17
|
|
pubmed:abstractText |
Artemisinin derivative-based combination therapy is expected to suppress the development of Plasmodium falciparum drug resistance in Africa. We have performed an artemether-lumefantrine (Coartem; Novartis) follow-up clinical trial in Zanzibar, in which pfcrt K76T and pfmdr1 N86Y frequencies were determined before drug administration and in all recurrent parasites during a follow-up period of 42 days. A significant increase in pfmdr1 86N was observed after exposure to the drug. This points to 86N as a potential marker of lumefantrine resistance in vivo, while suggesting that Coartem is not robust enough to avoid selection of resistance-associated mutations in some malarial settings.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ATP-Binding Cassette Transporters,
http://linkedlifedata.com/resource/pubmed/chemical/Antimalarials,
http://linkedlifedata.com/resource/pubmed/chemical/Artemisinins,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorenes,
http://linkedlifedata.com/resource/pubmed/chemical/Protozoan Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Sesquiterpenes,
http://linkedlifedata.com/resource/pubmed/chemical/artemether,
http://linkedlifedata.com/resource/pubmed/chemical/lumefantrine,
http://linkedlifedata.com/resource/pubmed/chemical/mdr gene protein, Plasmodium
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-1899
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
191
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1014-7
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15717281-ATP-Binding Cassette Transporters,
pubmed-meshheading:15717281-Alleles,
pubmed-meshheading:15717281-Animals,
pubmed-meshheading:15717281-Antimalarials,
pubmed-meshheading:15717281-Artemisinins,
pubmed-meshheading:15717281-Child,
pubmed-meshheading:15717281-Drug Resistance,
pubmed-meshheading:15717281-Drug Therapy, Combination,
pubmed-meshheading:15717281-Ethanolamines,
pubmed-meshheading:15717281-Fluorenes,
pubmed-meshheading:15717281-Genes, MDR,
pubmed-meshheading:15717281-Humans,
pubmed-meshheading:15717281-Infant,
pubmed-meshheading:15717281-Malaria, Falciparum,
pubmed-meshheading:15717281-Plasmodium falciparum,
pubmed-meshheading:15717281-Polymorphism, Single Nucleotide,
pubmed-meshheading:15717281-Protozoan Proteins,
pubmed-meshheading:15717281-Selection, Genetic,
pubmed-meshheading:15717281-Sesquiterpenes
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).
|
|
pubmed:affiliation |
Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden. christin.sisowath@medks.ki.se
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
